These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Effectiveness of oxybutynin hydrochloride in the treatment of enuresis nocturna--a clinical and urodynamic study. Koşar A; Arikan N; Dinçel C Scand J Urol Nephrol; 1999 Apr; 33(2):115-8. PubMed ID: 10360452 [TBL] [Abstract][Full Text] [Related]
29. [Neuropsychiatric adverse effects attributed to use of oxybutynin]. t'Veld BA; Kwee-Zuiderwijk WJ; van Puijenbroek EP; Stricker BH Ned Tijdschr Geneeskd; 1998 Mar; 142(11):590-2. PubMed ID: 9623118 [TBL] [Abstract][Full Text] [Related]
30. [The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization]. Yokoyama O; Ishiura Y; Nakamura Y; Ohkawa M Hinyokika Kiyo; 1995 Jul; 41(7):521-4. PubMed ID: 7668182 [TBL] [Abstract][Full Text] [Related]
31. [An update on clinical and therapeutic aspects of nocturnal enuresis]. Chiozza ML Pediatr Med Chir; 1997; 19(5):385-90. PubMed ID: 9493232 [TBL] [Abstract][Full Text] [Related]
33. Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia. Painter KA; Vates TS; Bukowski TP; Fleming P; Freedman AL; Smith CA; Gonzalez R; Perlmutter AD J Urol; 1996 Oct; 156(4):1459-62. PubMed ID: 8808907 [TBL] [Abstract][Full Text] [Related]
34. The effect of oxybutynin treatment on cognition in children with diurnal incontinence. Sommer BR; O'Hara R; Askari N; Kraemer HC; Kennedy WA J Urol; 2005 Jun; 173(6):2125-7. PubMed ID: 15879864 [TBL] [Abstract][Full Text] [Related]
35. [Individual conditions of pharmacogenic confusion conditions. Comparison of amitriptyline and clozapine]. Gabriel E; Küfferle B; Lenz G; Schuster P Psychiatr Clin (Basel); 1976; 9(1):5-13. PubMed ID: 1019368 [TBL] [Abstract][Full Text] [Related]
36. [Use of oral anticholinergic therapy in children under 1 years of age with high risk bladder]. Luque Mialdea R; Martín-Crespo R; Hernández E; Sánchez O; Cañizo A; Fernández A; Aparicio C; Blanco T; Cebrían J Cir Pediatr; 2005 Jan; 18(1):3-7. PubMed ID: 15901100 [TBL] [Abstract][Full Text] [Related]
37. [Use of driptan (oxybutinin) in patients with urgent forms of urination disorders]. Loran OB; Pushkar' DIu; Tevlin KP Urol Nefrol (Mosk); 1998; (6):24-6. PubMed ID: 10051823 [TBL] [Abstract][Full Text] [Related]
38. [Treatment with oxybutynin hydrochloride of urinary incontinence and hyperactive bladder conditions in children]. Aubert D; Cencig P; Royer M Ann Pediatr (Paris); 1986 Sep; 33(7):629-34. PubMed ID: 3777773 [No Abstract] [Full Text] [Related]
39. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population. Palmer LS; Zebold K; Firlit CF; Kaplan WE J Urol; 1997 Feb; 157(2):638-40. PubMed ID: 8996387 [TBL] [Abstract][Full Text] [Related]